🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Prantae Solutions saises seed round from IAN Group

EntrackrEntrackr · 7m ago
Prantae Solutions saises seed round from IAN Group
Medial

Deep-tech company Prantae Solutions has raised Rs 5 crore in a seed funding round led by the IAN Group, with participation from investors such as IAN Alpha Fund, Samir Kalia, Deepank Kumar, and Nitin Zamre. The fresh funds will be used to launch complementary diagnostic solutions for kidney health and diabetes care, enhance the product portfolio, and invest in research and development, Prantae Solutions said in a press release. Founded in 2015 by Sumona Karjee Mishra and Aseem Mishra, Prantae is a deep-tech-focused company emphasizing strong intellectual property and differentiated products. The company aims to transform healthcare into a realm of inclusivity and empowerment through next-generation diagnostic innovations. The Bhubaneswar-based company strives to break barriers in medical accessibility by developing cutting-edge, point-of-care solutions that deliver accurate, timely, and actionable insights. It is recognized for its commitment to innovation that enables early detection and proactive management of chronic conditions. According to market research, the point-of-care (POC) diagnostics market in India, valued at $1.41 billion in FY2024, is projected to grow at a CAGR of 8.47%, reaching $2.71 billion by FY2032. Globally, the market is expected to grow from $30.87 billion in 2023 to $51.19 billion by 2032. Prantae’s flagship product, Proflo-U, empowers kidney health assessment with its globally unmatched detection range for microalbumin to proteinuria levels. Powered by proprietary nanosensors, IoT, and AI technology, it offers calibration-free, cost-effective, and user-friendly testing solutions designed to improve patient outcomes and reduce healthcare costs. Prantae aims to establish a strong domestic presence before expanding to international markets. It also seeks to build highly differentiated point-of-care products and aspires to transform healthcare diagnostics, improving accessibility for millions worldwide.

Related News

MiClient raises seed round from IAN Group, others

EntrackrEntrackr · 1y ago
MiClient raises seed round from IAN Group, others
Medial

MiClient, an AI-driven B2B sales enablement platform, has raised Rs 3.9 crore in its seed funding round led by IAN Group with participation from Anicut, GSF, RTAF, and Keiretsu. Vikas Kuthiala and Pratik Mathurkar from IAN led the round. The round follows an initial pre-seed investment in October 2023 from 100x.VC. The proceeds will be used to build a stronger team and expand market presence across more geographies in India. In addition to market expansion, MiClient is developing an AI-based model to create quotations and invoices in seconds, further streamlining the sales process for its users. Led by Swati Sharma, MiClient’s easy-to-use CPQ platform helps sales teams close deals three times faster, with the average deal now closing in just 10 days. Expanding further into India’s industrial hubs, MiClient is executing a feet-on-the-street go-to-market strategy. MiClient is expanding into more industrial hubs across India using a direct sales approach. With over 150 customers and over 1,500 users, the company serves SMEs, particularly in the B2B manufacturing sector, with a user-friendly platform.

PlaySuper raises $500K in seed round led by IAN Group and 100X.VC

EntrackrEntrackr · 6m ago
PlaySuper raises $500K in seed round led by IAN Group and 100X.VC
Medial

Snippets PlaySuper raises $500K in seed round led by IAN Group and 100X.VC Gaming commerce startup PlaySuper has raised $500K in its seed round led by IAN Angel Fund and 100X.VC. The round also saw participation from angel investors including Uday Sodhi, KRS Jamwal, Pratham Mittal, Rajit Bhattacharya, and Ankit Das, among others. The proceeds will be used to accelerate product development, expand market reach, and strengthen hiring. PlaySuper is set to launch its next-gen, hyper-personalized in-game store, allowing easy integration without requiring updates. The Gurugram-based brand also plans to expand into Southeast Asia (SEA) within six months, followed by MENA and LATAM. Additionally, it will bring in a Product Head and expand its B2B partnerships team to onboard more gaming studios. Founded in April 2024 by Shouradeep Chakraborty, PlaySuper enables gamers to shop inside their favorite mobile games while playing. It integrates real-world shopping experiences within mobile games. Shouradeep and Upamanyu previously co-founded LectureNotes, an edtech platform that raised $2.5 million in 2022. They bring extensive experience from the gaming, Web3, and edtech sectors. Over the next year, the company will focus on launching its in-game store, scaling its reach into new markets, and deepening its collaborations with game developers.

IAN Group appoints Info Edge’s Chintan Thakkar as Group CEO

EntrackrEntrackr · 9d ago
IAN Group appoints Info Edge’s Chintan Thakkar as Group CEO
Medial

Early stage investment platform IAN Group has appointed Chintan Thakkar as Group CEO of IAN Group. The move comes as part of a broader strategy to augment the Group and build it to fuel future growth. Chintan will also provide critical guidance to the recently launched IAN Alpha Fund as a Senior Managing Partner for the Fund. Formerly the Group CFO & Whole time Director at Info Edge India, Chintan is a seasoned leader in finance, governance, and strategic growth and brings over three decades of experience, vision, and leadership to the IAN Group. At Info Edge, Chintan played a pivotal role in the company’s transformation from a small cap to large cap company with 18x market capitalisation growth, helped execute landmark capital market and M&A transactions, and was deeply involved in the company’s investments in early stage companies as well as in launching AIFs for startup investments. “IAN is one of India’s most respected names in the investment world. Its commitment to investing in innovation that addresses real problems or meets national strategic imperatives truly excites me. I look forward to making a significant contribution alongside the IAN Board and the team,” said Thakkar. IAN enables entrepreneurs to raise from Rs 50 lakhs to Rs 50 crore on a single platform, along with mentoring and global market access. The Group’s investment thesis has been to invest in startups in emerging sectors led by exceptional founders solving real problems or building for India’s strategic imperatives, while giving exceptional investor returns. Over the last 19 years, it claims to have consistently returned capital with multiples in high double digits.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 1m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.